featured
Effects of Mineralocorticoid Receptor Antagonism on Aortic Plaque Progression, LV Mass, and Fibrosis in Patients With Type 2 Diabetes and CKD
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Circulation
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Mineralocorticoid Receptor Antagonism Prevents Aortic Plaque Progression and Reduces Left Ventricular Mass and Fibrosis in Patients With Type 2 Diabetes and Chronic Kidney Disease: The MAGMA Trial
Circulation 2024 Aug 12;[EPub Ahead of Print], S Rajagopalan, M Dobre, JE Dazard, A Vergara-Martel, K Connelly, ME Farkouh, J Gaztanaga, H Conger, A Dever, L Razavi-Nematollahi, A Fares, G Pereira, J Edwards-Glenn, M Cameron, C Cameron, S Al-Kindi, RD Brook, B Pitt, M WeirFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.